The Venture Codex Logo

The Venture Codex

RD Fund

223 S. West Street, Suite 900, Raleigh, NC, 27603, United States

Overview

Accelerating outcomes for retinal degeneration through investments.

Founded

2018

Deals ยท 12mo

2

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series A
Series B

Geographic focus

France
United States

Sector focus

Business Development
Financial Services
Therapeutics

Investment portfolio

8rounds
NAMEDATESIZE
Osanni Bio
Jun 2026Participated
$190 MSeries B
Beacon Therapeutics
Jan 2026Participated
$75 MSeries C
Perceive Pharma
Feb 2025Led
$15 MSeries A
Perceive Biotherapeutics
Feb 2025Participated
$15 MSeries A
Perceive Biotherapeutics
Jan 2023Participated
$78 MSeries B
SparingVision
Sep 2022Participated
$75 MSeries B
SalioGen Therapeutics
Jan 2022Participated
$115 MSeries B
Opus Genetics
Sep 2021Led
$19 MSeed
Osanni Bio
Jun 2026Participated
$190 MSeries B
Beacon Therapeutics
Jan 2026Participated
$75 MSeries C
Perceive Pharma
Feb 2025Led
$15 MSeries A
Perceive Biotherapeutics
Feb 2025Participated
$15 MSeries A
Perceive Biotherapeutics
Jan 2023Participated
$78 MSeries B
SparingVision
Sep 2022Participated
$75 MSeries B
SalioGen Therapeutics
Jan 2022Participated
$115 MSeries B
Opus Genetics
Sep 2021Led
$19 MSeed
8
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

RD Fund: 8 funding rounds are recorded in the selected participation categories.All available history.
RD Fund: 8 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed10
Series A11
Series B04
Series C+01

Monthly Deal Activity

RD Fund: 8 deals are recorded across 62 months.All available history.
RD Fund: 8 deals are recorded across 62 months. All available history
MonthDeals
Sep '211
Oct '210
Nov '210
Dec '210
Jan '221
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '221
Oct '220
Nov '220
Dec '220
Jan '231
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '252
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '261
Feb '260
Mar '260
Apr '260
May '260
Jun '261
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

RD Fund: Health & Life Sciences is the largest displayed sector by deal count (8 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

RD Fund: Health & Life Sciences is the largest displayed sector by deal count (8 deals). All available history
SectorDeals
Health & Life Sciences8

Deal Size Distribution

RD Fund: 8 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

RD Fund: 8 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M3
$25M-$50M0
$50M-$100M3
$100M-$250M2
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

RD Fund: United States has the largest recorded deal count among the displayed regions (7 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

RD Fund: United States has the largest recorded deal count among the displayed regions (7 deals). All available history
RegionDeals
United States7
Europe1
RD Fund: 20 co-investors are shown, with Braidwell sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

RD Fund: 20 co-investors are shown, with Braidwell sharing 3 recorded deals. All available history
Co-investorShared deals
Braidwell3
Catalio Capital Management3
Deerfield Management3
Johnson & Johnson Innovation3
Google Ventures2
4BIO Capital1
Advent Life Sciences1
Bios Partners1
Bpifrance1
Cystic Fibrosis Foundation1
D1 Capital Partners1
EPIQ Capital Group1
Fidelity Management & Research Company1
Forbion1
GordonMD Global Investments1
Horowitz Group1
Invus1
Jeito Capital1
Manning Family Foundation1
Oxford Science Enterprises1

Investment Strategy

RD Fund: Led accounts for 25% and participating for 75% of round participation.All available history.
RD Fund: Led accounts for 25% and participating for 75% of round participation. All available history
CategoryDeals (count)Share (%)
Led225%
Participating675%
RD Fund: Single-lead accounts for 50% and co-led for 50% of lead dynamics.All available history.
RD Fund: Single-lead accounts for 50% and co-led for 50% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead150%
Co-led150%

Team

Benjamin Yerxa

CEO

Rusty Kelley

Managing Director